The mononucleosis diagnostics market is expected to register a CAGR of nearly 4.8% during the forecast period, 2022-2027.
The COVID-19 outbreak has substantially impacted the mononucleosis diagnostics market as the pandemic has increased the focus on the management of infectious diseases to limit their spread. This can be attributed to the fact that COVID-19 is associated with Epstein-Barr Virus (EBV) infections. For instance, as per an article titled, "Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation," published in September 2021, out of the 128 patients with COVID-19, 13.3 percent were infected with Epstein-Barr virus reactivation. As per an update published in February 2022, by the University Health Network, long COVID symptoms are also found in active EBV infections, and close to 70 percent of the COVID patients had the reactivated EBV. It further stated that EBV reactivation may be a cause of long COVID. Thus, such studies and updates indicate the demand for diagnosing EBV among the patient population is likely to increase, thereby, driving the market growth for mononucleosis diagnostics over the coming years.
Further, the major factors responsible for the growth of the global mononucleosis diagnostics market include the rising health awareness and knowledge among patients, technological advancements leading to faster diagnosis, and the rise in the adolescent population. These factors are expected to further contribute to the growth of the market over the forecast period.
Technological advancements leading to a faster diagnosis are primarily driving the market growth. For instance, in August 2020, Roche revealed that the United States Food and Drug Administration (FDA) had authorized the Cobas EBV test. This is the first quantitative in-vitro diagnostic test for Epstein-Barr virus (EBV) DNA in the United States. This authorization gives healthcare professionals a key tool in monitoring transplant patients at risk for complications from infections or reactivations of EBV, by providing the ability to run a large number of patient tests for this virus in a short period of time.
Nevertheless, the limitation of available tests for the diagnosis of mononucleosis is a major factor restraining the market's growth.
Key Market Trends
Monospot Test Segment by Test Type is Expected to Hold the Largest Market Share during the Forecast Period
By test type, the monospot test segment is expected to witness significant growth. A monospot test, also known as a heterophile antibody test, is a rapid test for the detection of infectious mononucleosis caused by the Epstein-Barr virus (EBV). This test is expected to hold the largest market share, owing to the benefits associated, such as non-interference with other tests, accurate results, rapid detection of antibodies, and cost-effectiveness. Furthermore, an article titled "Mononucleosis" published in StatPearls, in August 2021, stated that Mononucleosis is diagnosed using the monospot (or heterophile antibody) test, which is nearly 100 percent specific for the disease. This test's sensitivity is closer to 85 percent. Such studies greatly increase the acceptance of monospot test type among the patient population, thereby, contributing to the segment's growth.
In addition, the major market players are focusing on the development of advanced products, which is expected to boost the market's growth. For instance, Launch Diagnostics offers a rapid latex test for the detection of heterophile antibodies specific to Infectious Mononucleosis (IM). Thus, the above-mentioned factors are expected to drive the growth of this segment over the forecast period.
Asia-Pacific Accounted for the Highest Growth Rate in the Global Market
The Asia-Pacific region holds the highest growth rate for the mononucleosis diagnostic market, and it is expected to show a similar trend over the forecast period, without significant changes. The rising adolescent population in the region susceptible to EBV infection is one of the major factors that is expected to drive the growth of the market over the forecast period. For instance, according to an article published by Dr. Albert Saiz and Dr. Yolanda Blanco, in February 2022, stated that Mononucleosis is a disease that primarily affects adolescents and is caused by the Epstein-Barr virus. However, this virus is highly prevalent, with two maximum occurrence peaks in an individual's life, firstly around 3-4 years of age, and then secondly at 15-16 years of age. When an Epstein-Barr virus develops in childhood, the risk of developing Mononucleosis is quite low, but it is substantially higher in adolescence. This indicates that a large number of people are infected with the Epstein-Barr virus without being aware of the condition. As per a 2019 update by the United Nations (UN), in 2019, Central and Southern Asia were home to the largest number of youth (361 million), followed by Eastern and South-Eastern Asia (307 million). The high youth population indicates the significant demand for mononucleosis diagnostic tests.
In addition, the presence of key companies such as Cardinal Health and Abbott in the region is also contributing to the market's growth.
Thus, owing to the high number of adolescents, the region is expected to hold tremendous market opportunities over the forecast period.
The global mononucleosis diagnostics market is dominated by both major and small players. However, there are only a few small market players present in the niche segment of the market. The major market players such as Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Cardinal Health Inc. and Bio-Rad Laboratories are focusing on the development of advanced products in order to achieve faster detection.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Health Awareness and Knowledge among Patients
4.2.2 Technological Advancements Leading to Faster Diagnosis
4.2.3 Rise in the Adolescent Population
4.3 Market Restraints
4.3.1 Limitations of Available Tests for the Diagnosis of Mononucleosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Monospot Test
5.1.2 Complete Blood Count Test
5.1.3 Epstein Barr Virus (EBV) Antibody Test
5.2 By End User
5.2.3 Other End Users
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6.1.1 Abbott Laboratories
6.1.2 Arlington Scientific Inc.
6.1.3 Bio-Rad Laboratories Inc.
6.1.4 Cardinal Health Inc.
6.1.5 Danaher Corporation
6.1.6 Immunostics Inc.
6.1.7 Meridian Bioscience
6.1.8 Quidel Corporation
6.1.9 Sekisui Diagnostics
6.1.10 Thermo Fischer Scientific Inc.
6.1.11 Launch Diagnostics Limited
6.1.12 Beckman Coulter Inc.
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Arlington Scientific Inc.
- Bio-Rad Laboratories Inc.
- Cardinal Health Inc.
- Danaher Corporation
- Immunostics Inc.
- Meridian Bioscience
- Quidel Corporation
- Sekisui Diagnostics
- Thermo Fischer Scientific Inc.
- Launch Diagnostics Limited
- Beckman Coulter Inc.